Head-to-head evidence
Ibalizumab vs Semzuvolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: CD4 receptor · full HIV pipeline
Ibalizumab · Trogarzo
Marketed by Theratechnologies and partners
NCT02707861 · Phase 3 · completed
The study was nonrandomized, open-label, and had no comparator arm, so its results cannot reliably distinguish ibalizumab’s effects from those of the individualized background regimens or other factors. Its primary effectiveness endpoint was a short-term viral-load measure, and the reported results were descriptive rather than a controlled statistical comparison.
Next expected readout: December 2028 · NCT07635992 (registry estimate)
Semzuvolimab
Developed by United BioPharma
NCT04404049 · Phase 2 · status unknown
This is a small, open-label randomized study comparing two dosing schedules of add-on Semzuvolimab against standard therapy alone in people already on antiretroviral therapy. The primary measure is treatment-related side effects rather than a virologic or clinical outcome, and results are not yet available, so the evidence for Semzuvolimab's clinical benefit cannot yet be assessed.
Next expected readout: December 2026 · NCT04985890 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ibalizumab's landscape · Semzuvolimab's landscape